CTSO
Neutral signalScored 2026-09-09 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Cytosorbents Corporation
- Nom
- Cytosorbents Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $16.6M
- Employés
- 129
- PDG
- Phillip Chan
- Site web
- https://www.cytosorbents.com
- Marché
- BDMDBDSXECORICCMMDAINMTC
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 206 274 titres (~107 944,00 $ US)
- Insiders
- Chan Phillip P.Sobel Alan D.
- Total bought
-
$107,944
Avg buy (VWAP, 90d window) $0.46 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-15
- Last synced
-
2026-09-21 10:15:11
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-15 | Chan Phillip P. | Buy · P | 3,774 | $6.00 | $22,644 | Form 4 |
| 2026-09-15 | Sobel Alan D. | Buy · P | 100 | $6.01 | $601 | Form 4 |
| 2026-09-14 | Capponi Vincent | Buy · P | 273 | $5.90 | $1,611 | Form 4 |
| 2026-09-04 | Chan Phillip P. | Buy · P | 200,000 | $0.35 | $70,000 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-09 Drivers: fundamentals. Moteurs : fondamentaux.
Despite a meaningful insider cluster buy aligned with promising real-world clinical data (37% bleeding reduction in CABG) and FDA pre-submission activity, CTSO's severely distressed balance sheet — marked by persistent…
The first sentence of the analysis written for CTSO on 2026-09-09 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 2.13 · operating margin -38% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 71.5% | 69.9% | 70.6% | 59.8% | 72.5% | |
| Ebit Margin | -16.2% | -59.0% | -96.2% | -89.0% | -63.1% | |
| Ebitda Margin | -11.8% | -54.1% | -89.7% | -86.5% | -60.2% | |
| Operating Profit Margin | -38.4% | -46.2% | -102.8% | -90.9% | -56.7% | |
| Pretax Profit Margin | -23.2% | -63.0% | -96.7% | -97.7% | -63.1% | |
| Continuous Operations Profit Margin | -22.1% | -58.2% | -94.1% | -94.6% | -61.2% | |
| Net Profit Margin | -22.1% | -58.2% | -94.1% | -94.6% | -61.2% | |
| Bottom Line Profit Margin | -22.1% | -58.2% | -94.1% | -94.6% | -61.2% | |
| Current Ratio | 2.125 | 2.199 | 1.767 | 3.475 | 4.697 | |
| Quick Ratio | 1.581 | 1.921 | 1.514 | 3.119 | 4.349 | |
| Solvency Ratio | -0.172 | -0.523 | -0.908 | -1.146 | -0.870 | |
| Cash Ratio | 0.644 | 0.334 | 0.971 | 2.280 | 3.808 | |
| Price To Earnings Ratio | -4.915 | -2.395 | -1.708 | -2.067 | -7.351 | |
| Price To Earnings Growth Ratio | 0.075 | 0.058 | 0.128 | -0.065 | -0.040 | |
| Forward Price To Earnings Growth Ratio | 0.075 | 0.058 | 0.128 | -0.065 | -0.040 | |
| Price To Earnings Diluted Ratio | -4.915 | -2.395 | -1.708 | -2.067 | -7.351 | |
| Price To Earnings Diluted Growth Ratio | 0.075 | 0.058 | 0.128 | -0.065 | -0.040 | |
| Price To Book Ratio | 6.737 | 4.460 | 2.130 | 1.909 | 2.903 | |
| Price To Sales Ratio | 1.073 | 1.392 | 1.595 | 1.947 | 4.530 | |
| Price To Free Cash Flow Ratio | -3.171 | -3.367 | -2.194 | -1.947 | -9.935 | |
| Price To Operating Cash Flow Ratio | -3.213 | -3.433 | -2.289 | -2.392 | -12.972 | |
| Debt To Assets Ratio | 0.659 | 0.568 | 0.344 | 0.289 | 0.154 | |
| Debt To Equity Ratio | 4.932 | 2.421 | 0.787 | 0.516 | 0.221 | |
| Debt To Capital Ratio | 0.831 | 0.708 | 0.440 | 0.340 | 0.181 | |
| Long Term Debt To Capital Ratio | 0.738 | 0.558 | 0.098 | 0.124 | 0.000 | |
| Financial Leverage Ratio | 7.485 | 4.265 | 2.288 | 1.787 | 1.431 | |
| Working Capital Turnover Ratio | 3.265 | 3.104 | 1.766 | 0.929 | 0.653 | |
| Operating Cash Flow Ratio | -1.275 | -1.469 | -1.489 | -2.906 | -1.023 | |
| Operating Cash Flow Sales Ratio | -0.334 | -0.405 | -0.697 | -0.814 | -0.349 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.013 | 1.020 | 1.043 | 1.229 | 1.306 | |
| Debt Service Coverage Ratio | -1.514 | -12.562 | -10.183 | -265.384 | -41.063 | |
| Interest Coverage Ratio | -5.451 | -11.759 | -202.346 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -8.662 | -259.175 | -24.547 | |
| Operating Cash Flow Coverage Ratio | -0.425 | -0.536 | -1.182 | -1.547 | -1.013 | |
| Capital Expenditure Coverage Ratio | -75.470 | -50.741 | -23.130 | -4.374 | -3.271 | |
| Dividend Paid And Capex Coverage Ratio | -75.470 | -50.741 | -23.130 | -4.374 | -3.271 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -14.377 | -3.797 | -1.928 | -2.121 | -5.932 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 71.5% | ▲1.6% | ▲2.6% |
| Ebit Margin | -16.2% | ▲42.9% | ▲48.5% |
| Ebitda Margin | -11.8% | ▲42.4% | ▲48.7% |
| Operating Profit Margin | -38.4% | ▲7.8% | ▲28.6% |
| Pretax Profit Margin | -23.2% | ▲39.8% | ▲45.5% |
| Continuous Operations Profit Margin | -22.1% | ▲36.1% | ▲43.9% |
| Net Profit Margin | -22.1% | ▲36.1% | ▲43.9% |
| Bottom Line Profit Margin | -22.1% | ▲36.1% | ▲43.9% |
| Current Ratio | 2.125 | ▼-0.074 | ▼-0.727 |
| Quick Ratio | 1.581 | ▼-0.340 | ▼-0.915 |
| Solvency Ratio | -0.172 | ▲0.352 | ▲0.552 |
| Cash Ratio | 0.644 | ▲0.310 | ▼-0.964 |
| Price To Earnings Ratio | -4.915 | ▼-2.521 | ▼-1.228 |
| Price To Earnings Growth Ratio | 0.075 | ▲0.017 | ▲0.044 |
| Forward Price To Earnings Growth Ratio | 0.075 | ▲0.017 | ▲0.044 |
| Price To Earnings Diluted Ratio | -4.915 | ▼-2.521 | ▼-1.228 |
| Price To Earnings Diluted Growth Ratio | 0.075 | ▲0.017 | ▲0.044 |
| Price To Book Ratio | 6.737 | ▲2.277 | ▲3.109 |
| Price To Sales Ratio | 1.073 | ▼-0.319 | ▼-1.034 |
| Price To Free Cash Flow Ratio | -3.171 | ▲0.196 | ▲0.952 |
| Price To Operating Cash Flow Ratio | -3.213 | ▲0.220 | ▲1.647 |
| Debt To Assets Ratio | 0.659 | ▲0.091 | ▲0.256 |
| Debt To Equity Ratio | 4.932 | ▲2.510 | ▲3.156 |
| Debt To Capital Ratio | 0.831 | ▲0.124 | ▲0.331 |
| Long Term Debt To Capital Ratio | 0.739 | ▲0.181 | ▲0.435 |
| Financial Leverage Ratio | 7.485 | ▲3.220 | ▲4.034 |
| Working Capital Turnover Ratio | 3.265 | ▲0.161 | ▲1.321 |
| Operating Cash Flow Ratio | -1.275 | ▲0.194 | ▲0.357 |
| Operating Cash Flow Sales Ratio | -0.334 | ▲0.071 | ▲0.186 |
| Free Cash Flow Operating Cash Flow Ratio | 1.013 | ▼-0.006 | ▼-0.109 |
| Debt Service Coverage Ratio | -1.514 | ▲11.048 | ▲64.627 |
| Interest Coverage Ratio | -5.451 | ▲6.308 | ▲38.460 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲58.477 |
| Operating Cash Flow Coverage Ratio | -0.425 | ▲0.111 | ▲0.516 |
| Capital Expenditure Coverage Ratio | -75.469 | ▼-24.729 | ▼-44.072 |
| Dividend Paid And Capex Coverage Ratio | -75.469 | ▼-24.729 | ▼-44.072 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -14.377 | ▼-10.581 | ▼-8.746 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $39.8M | $49.5M | $49.6M | $67.5M | $181.7M | |
| Enterprise value | $62.6M | $73.1M | $53.8M | $63.6M | $143.4M | |
| EV / Sales | 1.69x | 2.06x | 1.73x | 1.83x | 3.57x | |
| EV / Op. cash flow | -5.06x | -5.07x | -2.48x | -2.25x | -10.24x | |
| EV / Free cash flow | -4.99x | -4.97x | -2.38x | -1.83x | -7.84x | |
| EV / EBITDA | -14.38x | -3.80x | -1.93x | -2.12x | -5.93x | |
| Net debt / EBITDA | -5.25x | -1.23x | -0.15x | 0.13x | 1.59x | |
| Current ratio | 2.12x | 2.20x | 1.77x | 3.48x | 4.70x | |
| Income quality | 1.51x | 0.70x | 0.76x | 0.86x | 0.57x | |
| Graham net-net | -$8 | -$10 | -$4 | $0 | $14 | |
| Tax burden | 95.3% | 92.5% | 97.3% | 96.8% | 97.1% | |
| Interest burden | 143.6% | 106.7% | 100.5% | 109.8% | 100.0% | |
| Working capital | $10.9M | $11.8M | $11.2M | $24.0M | $50.6M | |
| Invested capital | $32.9M | $36.0M | $37.2M | $51.8M | $73.9M | |
| Return on assets | -18.6% | -43.7% | -54.9% | -51.9% | -27.4% | |
| Operating ROA | -31.1% | -32.7% | -54.9% | -41.3% | -25.3% | |
| Return on tangible assets | -20.0% | -47.5% | -59.3% | -55.8% | -29.0% | |
| Return on equity | -138.9% | -186.5% | -125.7% | -92.8% | -39.2% | |
| Return on invested capital | -38.8% | -40.0% | -74.7% | -56.9% | -28.9% | |
| Return on capital employed | -41.3% | -43.8% | -82.5% | -58.9% | -30.0% | |
| Earnings yield | -20.6% | -41.8% | -59.0% | -48.6% | -13.5% | |
| Free cash flow yield | -31.5% | -29.7% | -45.6% | -51.4% | -10.1% | |
| Capex / Op. cash flow | -1.3% | -2.0% | -4.3% | -22.9% | -30.6% | |
| Capex / Depreciation | 17.2% | 16.2% | 46.2% | 570.5% | 379.0% | |
| Capex / Sales | 0.4% | 0.8% | 3.0% | 18.6% | 10.7% | |
| SG&A / Sales | 96.2% | 94.8% | 123.2% | 8.1% | 95.9% | |
| R&D / Sales | 13.7% | 21.4% | 50.2% | 43.6% | 40.8% | |
| Stock comp / Sales | 7.5% | 10.6% | 11.9% | 11.0% | 15.5% | |
| Intangibles / Total assets | 7.3% | 7.9% | 7.3% | 6.9% | 5.3% | |
| Days sales outstanding | 74d | 75d | 71d | 60d | 41d | |
| Days payables outstanding | 99d | 114d | 152d | 43d | 93d | |
| Operating cycle | 257d | 168d | 218d | 150d | 199d | |
| Cash conversion cycle | 158d | 54d | 66d | 107d | 106d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-10 CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference PRINCETON, N.J., Sept. 10, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming H.C.
- 2026-09-10 Head-To-Head Survey: Biomerica (NASDAQ:BMRA) versus Cytosorbents (NASDAQ:CTSO) Cytosorbents (NASDAQ: CTSO - Get Free Report) and Biomerica (NASDAQ: BMRA - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Profitability This table compares Cytosorbents and Biomerica''s net margins,
- 2026-09-04 CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. Dr. Phillip Chan, CEO and Peter Mariani, CFO will be attending the conference, delivering an investor presentation and participating in scheduled 1-on-1 meetings with investors.
- 2026-09-03 CytoSorbents Announces Reverse Stock Split Reverse Stock Split Previously Approved by Shareholders; Intended to Support Compliance with Nasdaq''s $1.00 Minimum Bid Price Requirement Expected to Become Effective and Trade on Split-Adjusted Basis at the Market Open on September 8, 2026 PRINCETON, N.J., Sept. 3, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it will effect a one-for-twenty (1:20) reverse stock split (the "Reverse Stock Split") of its common stock, par value $0.001 per share (the "Common Stock").
- 2026-09-02 CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings reinforce results from the STAR-T trial and are expected to form a core component of additional real-world evidence planned for a new U.S. FDA De Novo submission for DrugSorb-ATR® Recent FDA Pre-Submission meetings provided constructive feedback on potential U.S. regulatory pathways for DrugSorb-ATR for separate applications for ticagrelor and direct oral anticoagulant removal in urgent cardiac surgery PRINCETON, N.J., Sept. 2, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in severe perioperative bleeding among patients undergoing urgent coronary artery bypass grafting (CABG) surgery on the blood thinner, ticagrelor (Brilinta®/Brilique®, AstraZeneca).
- 2026-08-07 Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript
- 2026-08-06 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., Aug. 6, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2026, recent business highlights, and provides a regulatory update.
- 2026-07-20 CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights PRINCETON, N.J., July 20, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2026 financial results and recent business highlights after the market close on Thursday, August 6, 2026.